Posts

Cannabis use while trying to conceive: a prospective cohort study evaluating associations with fecundability, live birth and pregnancy loss

Is cannabis use assessed via urinary metabolites and self-report during preconception associated with fecundability, live birth and pregnancy loss? Preconception cannabis use was associated with reduced fecundability among women with a history of pregnancy loss attempting pregnancy despite an increased frequency of intercourse. Cannabis use continues to rise despite limited evidence of safety during critical windows of pregnancy establishment. While existing studies suggest that self-reported cannabis use is not associated with fecundability, self-report may not be reliable. Prospective cohort study was carried out including 1228 women followed for up to six cycles while attempting pregnancy (2006 to 2012), and throughout pregnancy if they conceived.

Cannabis use among patients with alopecia areata: a cross-sectional survey study

Little is known about cannabis use among patients with alopecia areata (AA). These patients often experience significant psychosocial burden and may seek alternative therapies beyond that of traditional medical treatments, such as cannabis. This was a cross-sectional study conducted from March 9, 2021, to March 22, 2021, using a web-based survey distributed to adult patients with AA using the National AA Foundation’s email listserv and social media platforms.

Impact of Marijuana Use on Lung Health

The widespread use of marijuana in the context of increasing legalization has both short- and long-term health implications. Although various modes of marijuana use—smoked, vaped, or ingested—may lead to a wide scope of potential systemic effects, we focus here on inhalational use of marijuana as the most common mode with the lung as the organ that is most directly exposed to its effects. Smoked marijuana has been associated with symptoms of chronic bronchitis and histopathologic changes in airway epithelium, but without consistent evidence of long-term decline in pulmonary function. Its role in immunomodulation, both for risk of infection and protection against a hyperinflammatory host response to infection, has been suggested in animal models and in vitro without conclusive extrapolation to humans. Marijuana smoke contains carcinogens like those found in tobacco, raising concern about its role in lung cancer, but evidence is mixed and made challenging by concurrent tobacco use.

Prevalence and Effect of Cannabinoids in Pain Management for Hand Pathologies

Cannabinoids are a diverse group of compounds under investigation for various medical purposes, including analgesia. Given the evolving landscape of cannabinoid use, we aimed to analyze their prevalence and effect in pain management among urban orthopedic hand patients. An electronic survey was administered to 122 new patients presenting to the orthopedic hand clinic of a major urban academic hospital. Demographic data, numerical rating scale pain scores, cannabinoid usage, and other concomitant pain regimens were recorded.

Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease

Breast cancer is the most frequently diagnosed cancer and the leading cause of death by cancer among women worldwide. The prognosis of the disease and patients’ response to different types of therapies varies in different subgroups of this heterogeneous disease. The subgroups are based on histological and molecular characteristics of the tumor, especially the expression of estrogen (ER) and progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Hormone-dependent breast cancer, determined predominantly by the presence of ER, is the most common type of breast cancer. Patients with hormone-dependent breast cancer have an available targeted therapy, however, tumor cells can develop resistance to the therapy, which is a major obstacle limiting the success of treatment and enabling relapse to metastatic disease. …

Prevalence of Metabolic Syndrome Among Emerging Adult Cannabis Users by Race/Ethnicity: Analysis of the 2009-2018 National Health and Nutrition Examination Surveys

Association between cannabis use and metabolic syndrome (MetS) has been documented; yet variation by race/ethnicity is understudied. We examined cannabis use and MetS by race/ethnicity among emerging adults (18-25 years old), the age group with the highest prevalence of cannabis use.

Medical Cannabis for Patients Over Age 50: A Multi-site, Prospective Study of Patterns of Use and Health Outcomes

Cannabis is being used as a therapeutic option by patients around the globe, and older patients represent a rapidly growing subset of this population. This study aims to assess the patterns of medical cannabis use in patients over 50 years of age and its effect on health outcomes such as pain, sleep, quality of life, and co-medication.

Medical Cannabis Is Not Associated with a Decrease in Activities of Daily Living in Older Adults

The proportion of older adults using medical cannabis is rising. Therefore, we aimed to assess the effects of herbal medical cannabis on the functional status of older adults. We conducted a prospective observational study of patients aged 65 years or older that initiated cannabis treatment for different indications, mostly chronic non-cancer pain, during 2018–2020 in a specialized geriatric clinic. The outcomes assessed were activities of daily living (ADL), instrumental activities of daily living (IADL), pain intensity, geriatric depression scale, chronic medication use, and adverse events at six months. A cohort of 119 patients began cannabis treatment: the mean age was 79.3 ± 8.5 and
74 (62.2%) were female. Of the cohort, 43 (36.1%) experienced adverse effects due to cannabis use and 2 (1.7%) required medical attention. The mean ADL scores before and after treatment were 4.4 ± 1.8 and 4.5 ± 1.8, respectively (p = 0.27), and the mean IADL scores before and after treatment were 4.1 ± 2.6 and 4.7 ± 3, respectively (p = 0.02). We concluded that medical cannabis in older adults has a number of serious adverse events, but was not associated with a decrease in functional status, as illustrated by ADL and IADL scores after six months of continuous treatment.

Implications and quantifications of marijuana use regarding neonatal outcomes

Legalization of marijuana is increasingly steadily which supports more widespread use and a growing perception of less risk of harm, however study of its effects on newborns when used by pregnant women is still lacking. Current physicians and health care practitioners are not fully informed to advise best practice regarding marijuana use during pregnancy. Additionally, methods to measure marijuana usage and effects are still limited and require further development, therefore assessment of whether not pregnant women should use marijuana products is timely and important.

Long-term efficacy and adverse effects of cannabidiol in adjuvant treatment of drug-resistant epilepsy: a systematic review and meta-analysis

Epilepsy is one of the most common chronic brain diseases. Almost one-thirdof patients have drug-resistant epilepsy (DRE). Cannabidiol is being considered as a potential novel drug for treating DRE. To investigate long-term efficacy and safety of cannabidiol in treatment of DRE and the differences in cannabidiol treatment among patients with different characteristics.

Association between marijuana use and kidney stone: a cross-sectional study of NHANES 2009 to 2018

The purpose of this investigation is to determine whether regular marijuana use is related to history of kidney stones in the US population. Data were obtained from the National Health and Nutrition Examination Survey (NHANES) from 2009 to 2018. Kidney stone and marijuana use data were collected from self-report questionnaires. Multivariate logistic regression and multiple sensitivity analyses were applied to examine the relationship between marijuana usage and kidney stones.

Shower power: a case report of cannabinoid hyperemesis syndrome

Cannabis use is becoming more common globally, making it important for physicians to be aware of cannabinoid hyperemesis syndrome (CHS). CHS presents in chronic cannabis users, typically under the age of 50, and entails a severe cyclic nausea and vomiting pattern with abdominal pain but normal bowel habits. Symptoms typically predominate in the morning, are relieved by hot baths or showers, and resolve with discontinuation of cannabis use. This report details a case of a 32-year-old woman who presented to the emergency department at a large Canadian hospital with severe nausea, vomiting and a history of regular use of marijuana cigarettes. In an attempt to alleviate her symptoms she reported taking frequent hot baths and using as many as five marijuana cigarettes per day. The patient’s clinical presentation, chronic daily use of marijuana and relief of symptoms with hot baths led to the diagnosis of CHS. The antiemetic properties of cannabis are widely known in the community, meaning patients may not associate marijuana use with their symptoms. Additionally, cyclic vomiting syndrome is present in many different conditions, making physician awareness of this syndrome crucial. Recognition and diagnosis of this condition can prevent unnecessary, costly diagnostic tests, and provide an opportunity to initiate counselling on cessation.